Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting (Q35693273)

9 August 2017

1 reference

title

Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting (English)

1 reference

9 August 2017

1 reference

2

Caroline M Perry

1 reference

9 August 2017

Toni M Dando

1

1 reference

9 August 2017

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

64

1 reference

9 August 2017

7

1 reference

9 August 2017

777-794

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464070-00013

9 August 2017

0 references

cites work

Potential of substance P antagonists as antiemetics

1 reference

12 December 2020

Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

1 reference

12 December 2020

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

1 reference

12 December 2020

ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)

1 reference

12 December 2020

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical

1 reference

12 December 2020

New agents, new treatment, and antiemetic therapy

1 reference

12 December 2020

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

1 reference

12 December 2020

Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development

1 reference

12 December 2020

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

1 reference

12 December 2020

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

12 December 2020

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

12 December 2020

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

12 December 2020

Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control

1 reference

12 December 2020

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

1 reference

12 December 2020

Treatment of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs

1 reference

12 December 2020

Antiemetic Therapy in Patients Receiving Cancer Chemotherapy

1 reference

12 December 2020

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

1 reference

12 December 2020

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

1 reference

12 December 2020

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

12 December 2020

Why Do We Need Another Antiemetic? Just Ask

1 reference

12 December 2020

Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.

1 reference

12 December 2020

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

1 reference

12 December 2020

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

12 December 2020

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting

1 reference

12 December 2020

Progress in preventing chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects

1 reference

12 December 2020

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

1 reference

12 December 2020

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

1 reference

12 December 2020

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

1 reference

12 December 2020

The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.

1 reference

12 December 2020

10.2165/00003495-200464070-00013

Identifiers

DOI

1 reference

PubMed ID

15025555

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

15025555